Table 1.
CNAs frequently detected in metastases.
| Genomic CNAs |
||||||||
|---|---|---|---|---|---|---|---|---|
| Gain/Loss | Chromosomal region (bp)7 | Size (bp) | Primary ccRCCs1 (n = 20) (%) | Metastases2 (n = 20) (%) | McNemar test (P value) | Recurrence-free survival3 (P value) | Cancer-specific survival4 (P value) | |
| Gains | ||||||||
| 1q21.1 | 143,706,582–143,787,563 | (1q21.1) | 80,981 | 2 (10) | 8 (40) | 0.031 | NS | NS |
| 11p15.5 | 274,838–305,091 | (11p15.5) | 30,253 | 1 (5) | 7 (35) | 0.031 | NS | NS |
| 16p13.3 | 3,346,012–4,759,330 | (16p13.3) | 1,413,318 | 3 (15) | 10 (50) | 0.039 | NS | NS |
| 4,904,632–4,904,686 | (16p13.3) | 54 | 3 (15) | 10 (50) | 0.039 | NS | NS | |
| Losses | ||||||||
| 1p32.1-p31.3 | 60,310,897–64,442,244 | (1p32.1-p31.3) | 4,131,347 | 2 (10) | 8 (40) | 0.031 | NS | NS |
| 1p31.3-p21.1 | 64,788,851–86,944,864 | (1p31.3-p22.3) | 22,156,013 | 3 (15) | 9 (45) | 0.031 | NS | NS |
| 86,968,324–86,968,383 | (1p22.3) | 59 | 2 (10) | 9 (45) | 0.016 | NS | NS | |
| 87,017,943–104,653,907 | (1p22.3-p21.1) | 17,635,964 | 2 (10) | 8 (40) | 0.031 | NS | NS | |
| 4q13.3 | 70,439,721–75,081,744 | (4q13.3) | 4,642,023 | 8 (40) | 14 (70) | 0.031 | NS | NS |
| 4q13.3-q35.1 | 75,122,238–167,949,936 | (4q13.3-q32.3) | 92,827,698 | 8 (40) | 14 (70) | 0.031 | NS | NS |
| 168,158,098–169,858,273 | (4q32.3) | 1,700,175 | 8 (40) | 15 (75) | 0.016 | NS | NS | |
| 169,986,365–182,690,789 | (4q32.3-q35.1) | 12,704,424 | 9 (45) | 15 (75) | 0.031 | NS | NS | |
| 4q35.2 | 187,416,579–188,522,372 | (4q35.2) | 1,105,793 | 5 (25) | 12 (60) | 0.016 | 0.04555 | NS |
| 189,694,932–190,351,920 | (4q35.2) | 656,988 | 4 (20) | 10 (50) | 0.031 | 0.04615 | NS | |
| 190,887,201–191,121,254 | (4q35.2) | 234,053 | 3 (15) | 9 (45) | 0.031 | NS | NS | |
| 6q22.1-q22.31 | 114,483,498–119,876,171 | (6q22.1-q22.31) | 5,392,673 | 4 (20) | 10 (50) | 0.031 | NS | NS |
| 6q22.31-q25.1 | 121,268,217–150,251,493 | (6q22.31-q25.1) | 28,983,276 | 4 (20) | 10 (50) | 0.031 | NS | NS |
| 8p23.1 | 10,323,367–10,323,426 | (8p23.1) | 59 | 9 (45) | 16 (80) | 0.039 | NS | NS |
| 8p23.1-p11.21 | 11,721,042–31,607,604 | (8p23.1-p12) | 19,886,562 | 10 (50) | 17 (85) | 0.016 | NS | NS |
| 31,616,802–33,525,017 | (8p12) | 1,908,215 | 9 (45) | 17 (85) | 0.008 | NS | NS | |
| 33,568,440–33,575,306 | (8p12) | 6866 | 9 (45) | 16 (80) | 0.039 | NS | NS | |
| 34,072,415–36,481,098 | (8p12) | 2,408,683 | 9 (45) | 17 (85) | 0.008 | NS | NS | |
| 36,822,238–36,912,314 | (8p12) | 90,076 | 9 (45) | 16 (80) | 0.039 | NS | NS | |
| 36,973,293–38,988,375 | (8p12-p11.23) | 2,015,082 | 9 (45) | 17 (85) | 0.008 | NS | NS | |
| 39,018,630–40,131,529 | (8p11.23-p11.21) | 1,112,899 | 9 (45) | 16 (80) | 0.016 | NS | NS | |
| 40,208,325–40,802,376 | (8p11.21) | 594,051 | 8 (40) | 15 (75) | 0.039 | NS | NS | |
| 9p24.3-p13.3 | 2,078,528–2,078,587 | (9p24.3) | 59 | 9 (45) | 16 (80) | 0.039 | 0.01966 | 0.00366 |
| 2,109,502–2,822,760 | (9p24.3-p24.2) | 713,258 | 9 (45) | 17 (85) | 0.021 | 0.01966 | 0.00366 | |
| 2,906,200–5,500,754 | (9p24.2-p24.1) | 2,594,554 | 10 (50) | 17 (85) | 0.039 | 0.00896 | 0.00066 | |
| 5,536,660–32,972,853 | (9p24.1-p13.3) | 27,436,193 | 10 (50) | 18 (90) | 0.008 | 0.00896 | 0.00066 | |
| 32,978,063–33,019,061 | (9p13.3) | 40,998 | 10 (50) | 17 (85) | 0.039 | 0.00896 | 0.00066 | |
| 33,027,699–34,076,033 | (9p13.3) | 1,048,334 | 9 (45) | 16 (80) | 0.016 | 0.01966 | 0.00366 | |
Underlining indicates the CNA for which the frequency of metastasis was the most significant relative to the primary tumor and associated with poor prognosis.
Primary ccRCCs in which each CNA was detected.
Metastases in which each CNA was detected.
Comparison of recurrence-free survival rates between patients with and without CNAs in their primary ccRCCs by log-rank test.
Comparison of cancer-specific survival rates between patients with and without CNAs in their primary ccRCCs by log-rank test.
Patients without CNAs showed lower recurrence-free survival rates than the patients with CNAs.
CNAs that were associated with significantly lower recurrence-free survival rates and cancer-specific survival rates if detected in the primary tumors.
Genomic locations are based on the human reference genome UCSC hg18 assembly.